The content for this activity is based on the satellite symposium, “Current Strategies for the Long-term Assessment, Monitoring, and Management for Cystic Fibrosis Patients Treated with CFTR Modulator Therapy” that was presented at the 39th European Cystic Fibrosis Society Conference on June 10, 2016. The emergence of novel targeted agents, that directly correct CFTR loss function alleles, has created new treatment opportunities for patients with cystic fibrosis with advanced disease.
Elsevier CME is committed to providing the topics necessary to stay up-to-date in the field of infectious diseases.
The treatment of HCV has undergone a dramatic evolution in the last several years. Whereas traditional interferon-based therapy for HCV was limited by poor efficacy and a heavy burden of side effects, interferon-free antiviral regimens are now available, offering new options for patients and altering the approach to this serious disease. The rapid pace of drug research, development, and approval requires frequent updates to treatment guidelines and leaves many clinicians wondering when, in whom, and how to manage chronic HCV infection.